A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. (Q39128672)

9 September 2017

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. (English)

1 reference

9 September 2017

phase II clinical trial

0 references

1 reference

1

Patrick Marcellin

1 reference

9 September 2017

Herve Mommeja-Marin

2

1 reference

9 September 2017

Stephen L Sacks

3

1 reference

9 September 2017

George K K Lau

4

1 reference

9 September 2017

Daniel Sereni

5

1 reference

9 September 2017

Jean-Pierre Bronowicki

6

1 reference

9 September 2017

Brian Conway

7

1 reference

9 September 2017

Christian Trepo

8

1 reference

9 September 2017

M Robert Blum

9

1 reference

9 September 2017

Byung Chul Yoo

10

1 reference

9 September 2017

Elsa Mondou

11

1 reference

9 September 2017

Jeff Sorbel

12

1 reference

9 September 2017

Andrea Snow

13

1 reference

9 September 2017

Franck Rousseau

14

1 reference

9 September 2017

Hyo-Suk Lee

15

1 reference

9 September 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

9 September 2017

1 reference

9 September 2017

40

1 reference

9 September 2017

140-148

1 reference

9 September 2017

1

1 reference

Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus

9 September 2017

1 reference

Hepatitis B virus infection

21 January 2018

1 reference

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

7 January 2021

Protein kinase C-dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells

1 reference

7 January 2021

Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

7 January 2021

In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil

1 reference

7 January 2021

Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil

1 reference

7 January 2021

Structure--activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl)pyrimidine nucleosides as anti-hepatitis B virus agents

1 reference

7 January 2021

Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase

1 reference

7 January 2021

Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).

1 reference

7 January 2021

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study.

1 reference

7 January 2021

Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.

1 reference

7 January 2021

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

1 reference

7 January 2021

Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations.

1 reference

7 January 2021

Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.20257

1 reference

9 September 2017

1 reference